Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

Management of Advanced Pancreatic Cancer: Overview of Key Trials and…

Integrity CE

E. O’Reilly

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

ASCO® GI 2025 Summary: mCRC Case-Based Discussion - Lessons Learned

Insights from 2025 ASCO® GI Annual Meeting

R. Mehta, M. Shah

Frontline Gemcitabine/Nab-Paclitaxel vs. 5-FU/LCV/Liposomal Irinotec…

ecancer

E. Dotan

ASCO® 2025 Summary: CRC Highlights Including ATOMIC, BREAKWATER, and…

2025 ASCO® Annual Meeting Insights Hub

C. Eng

ASCO® GI 2025 Insights: Ph3 BREAKWATER Study - Encorafenib + Cetuxim…

Insights from 2025 ASCO® GI Annual Meeting

S. Kopetz

ASCO® 2025 Summary: Clinical Insights & Discussion on Key CRC Trials

2025 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi

Year in Review: CRC & Anal Cancer

OncoAlert

C. Eng

Treatment Approaches for KRAS-Mutated mCRC

Ibrahim Sahin

ASCO® 2025 Summary: Innovations and Challenges in Targeting Treatmen…

2025 ASCO® Annual Meeting Insights Hub

K. Reiss

Targeting KRAS in Pancreatic Cancer: A Long But Successful Climb

Integrity CE

N. Saba Azad

Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomi…

Fox Chase Cancer Center

J. Reuss

ASCO® GI 2025 Summary: Key Trial Highlights in mCRC and Clinical Ins…

Insights from 2025 ASCO® GI Annual Meeting

R. Kim, T. Biachi

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

2024 ESMO Annual Meeting Insights Hub

H. Hochster

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

ASCO® GI 2025 Insights: Impact of UGT1A1*28 Polymorphism on Treatmen…

Insights from 2025 ASCO® GI Annual Meeting

M. Abdelrahim

Year in Review: Metastatic Pancreatic Cancer

OncoAlert

B. Westphalen

FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCL…

Memorial Sloan Kettering Cancer Center

A. Schram